4-[[4-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]苯基]甲基]-1,2-恶唑烷-3,5-二酮 | 170861-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-[[4-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]苯基]甲基]-1,2-恶唑烷-3,5-二酮
• 英文名称: reglitazar
• 英文别名: 4-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl}-isoxazolidine-3,5-dione；4-[4-[2-(2-phenyl-5-methyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxazolidinedione；4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxazolidinedione；JTT-501；4-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzyl]isoxazolidin-3,5-dione；4-[4-[2-(5-methyl-2-phenyl-oxazol-4-yl)ethoxy]benzyl]-3,5-isoxazolidinedione；reglixane；4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione
• CAS: 170861-63-9
• 化学式: C₂₂H₂₀N₂O₅
• 分子量: 392.411
• InChiKey: QBQLYIISSRXYKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  90.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[[4-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]苯基]甲基]-1,2-恶唑烷-3,5-二酮 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以83%的产率得到2-Carbamoyl-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propionic acid
  参考文献：
  名称：

  Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents

  摘要：

  Isoxazolidine-3,5-dione 2 (JTT-501), one of the cyclic malonic acid derivatives, was found to decrease blood glucose at an oral dose of 38 mg/kg/day in KKA(y) mice and is currently undergoing evaluation in phase II clinical trials. Further studies on a series of malonic acids and related compounds showed that the 1,3-dicarbonyl structure was important for insulin-sensitizing activity. Dimethyl malonate 10, which was selected as a successor for 2, was the optimum compound in a series of 1,3-dicarbonyl compounds and was more potent than the corresponding thiazolidine-2,4-dione 1.

  DOI：

  10.1021/jm970771m
• 作为产物：
  描述：

  4-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]苯甲醛 在 palladium on activated charcoal 氢气 、 羟胺 、 哌啶乙酸盐 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 甲苯 为溶剂， 反应 7.0h， 生成 4-[[4-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]苯基]甲基]-1,2-恶唑烷-3,5-二酮
  参考文献：
  名称：

  Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents

  摘要：

  Isoxazolidine-3,5-dione 2 (JTT-501), one of the cyclic malonic acid derivatives, was found to decrease blood glucose at an oral dose of 38 mg/kg/day in KKA(y) mice and is currently undergoing evaluation in phase II clinical trials. Further studies on a series of malonic acids and related compounds showed that the 1,3-dicarbonyl structure was important for insulin-sensitizing activity. Dimethyl malonate 10, which was selected as a successor for 2, was the optimum compound in a series of 1,3-dicarbonyl compounds and was more potent than the corresponding thiazolidine-2,4-dione 1.

  DOI：

  10.1021/jm970771m

文献信息

• 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES
  申请人：Klein Markus

  公开号：US20100305142A1

  公开（公告）日：2010-12-02

  Novel compounds of the formula (I), in which W, T, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the meanings indicated in Patent Claim ( 1 ), are suitable as antidiabetics.

  化合物的新颖结构如下（I）式，其中W，T，R1，R2，R3，R4，R5和R6的含义如专利权要求（1）中所示，适用作为抗糖尿病药物。
• Benzimidazole Derivatives
  申请人：Burgdorf Lars Thore

  公开号：US20100016372A1

  公开（公告）日：2010-01-21

  Novel compounds of the formula I (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R, Q, W, X and Z have the meanings indicated in Patent Claim 1 , are suitable as antidiabetics.

  公式I（I）的新化合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R，Q，W，X和Z的含义如专利权要求书中所示，适用于抗糖尿病药物。
• IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES
  申请人：Klein Markus

  公开号：US20100249151A1

  公开（公告）日：2010-09-30

  Novel compounds of the formula (I), in which W, T, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X 7 have the meanings indicated in Patent Claim 1 , are suitable as antidiabetics.

  化合物的新颖结构式（I），其中W、T、R1、R2、R3、R4、R5、R6和X7的含义如专利权要求书中所示，适用于抗糖尿病药物。
• Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110178134A1

  公开（公告）日：2011-07-21

  The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  本发明涉及具有所述意义的公式（I）的化合物，以及它们的生理相容性盐。所述化合物适用于例如作为抗肥胖药物和治疗心血管代谢综合征。
• CARBAMOYLBENZOTRIAZOLE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
  申请人：Petry Stefan

  公开号：US20080287503A1

  公开（公告）日：2008-11-20

  The invention relates to carbamoylbenzotriazole derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.

  这项发明涉及一般式(I)的氨基甲酰基苯并三唑衍生物，其在描述中被定义，以及它们的药用盐和作为药物的用途。